longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

Tip Ranks
Jun 22, 2026 at 02:55 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

In a report released today, from Mizuho Securities maintained a Buy rating on Iovance Biotherapeutics, with a price target of $10.00.TipRanks' Prime Week Sale - 70% Off Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.80.

In a report released today, from Mizuho Securities maintained a Buy rating on Iovance Biotherapeutics, with a price target of $10.00.

TipRanks' Prime Week Sale - 70% Off

  • Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
  • Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.80.

Login to unlock498characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

Iovance Biotherapeautics

Iovance Biotherapeautics

USIOVA

+7.67%

Mizuho Financial

Mizuho Financial

USMFG

LongbridgeAI